PURPOSE: This was a phase I trial to determine the maximum tolerated dose and toxicity of deforolimus (AP23573, MK-8669), an inhibitor of mammalian target of rapamycin (mTOR). The pharmacokinetics, pharmacodynamics, and antineoplastic effects were also studied. EXPERIMENTAL DESIGN: Deforolimus was administered intravenously over 30 min every 7 days according to a flat dosing schedule. Dose was escalated according to an accelerated titration design. Patients remained on study until disease progression as long as they tolerated the drug without significant toxicities. RESULTS: Forty-six patients were enrolled on the study. Common side effects included fatigue, anorexia, and mucositis. The maximum tolerated dose was 75 mg and mucositis was the dose-limiting toxicity. Similar to other mTOR inhibitors, deforolimus exhibited nonlinear pharmacokinetics and a prolonged half-life. Among 34 patients evaluable for response, 1 patient had a partial response, 21 patients had stable disease, and 12 had progressed. Percent change in tumor size was significantly associated with AUC (P=0.015). A significant association was also detected for maximum change in cholesterol within the first two cycles of therapy and change in tumor size (r=-0.38; P=0.029). CONCLUSIONS: Deforolimus was well tolerated on the schedule tested in this trial with toxicity and pharmacokinetic profiles that were similar to that of other mTOR inhibitors. Additional phase II studies are needed to determine if deforolimus is superior to other mTOR inhibitors in terms of efficacy. The change in serum cholesterol as a potential biomarker of activity should be studied further.
PURPOSE: This was a phase I trial to determine the maximum tolerated dose and toxicity of deforolimus (AP23573, MK-8669), an inhibitor of mammalian target of rapamycin (mTOR). The pharmacokinetics, pharmacodynamics, and antineoplastic effects were also studied. EXPERIMENTAL DESIGN: Deforolimus was administered intravenously over 30 min every 7 days according to a flat dosing schedule. Dose was escalated according to an accelerated titration design. Patients remained on study until disease progression as long as they tolerated the drug without significant toxicities. RESULTS: Forty-six patients were enrolled on the study. Common side effects included fatigue, anorexia, and mucositis. The maximum tolerated dose was 75 mg and mucositis was the dose-limiting toxicity. Similar to other mTOR inhibitors, deforolimus exhibited nonlinear pharmacokinetics and a prolonged half-life. Among 34 patients evaluable for response, 1 patient had a partial response, 21 patients had stable disease, and 12 had progressed. Percent change in tumor size was significantly associated with AUC (P=0.015). A significant association was also detected for maximum change in cholesterol within the first two cycles of therapy and change in tumor size (r=-0.38; P=0.029). CONCLUSIONS: Deforolimus was well tolerated on the schedule tested in this trial with toxicity and pharmacokinetic profiles that were similar to that of other mTOR inhibitors. Additional phase II studies are needed to determine if deforolimus is superior to other mTOR inhibitors in terms of efficacy. The change in serum cholesterol as a potential biomarker of activity should be studied further.
Authors: David A Rizzieri; Eric Feldman; John F Dipersio; Nashat Gabrail; Wendy Stock; Roger Strair; Victor M Rivera; Maher Albitar; Camille L Bedrosian; Francis J Giles Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler Journal: Nat Med Date: 2002-02 Impact factor: 53.440
Authors: M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: H Hosoi; M B Dilling; T Shikata; L N Liu; L Shu; R A Ashmun; G S Germain; R T Abraham; P J Houghton Journal: Cancer Res Date: 1999-02-15 Impact factor: 12.701
Authors: Michael B Atkins; Manuel Hidalgo; Walter M Stadler; Theodore F Logan; Janice P Dutcher; Gary R Hudes; Young Park; Song-Heng Liou; Bonnie Marshall; Joseph P Boni; Gary Dukart; Matthew L Sherman Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Naifa L Busaidy; Azeez Farooki; Afshin Dowlati; John P Perentesis; Janet E Dancey; Laurence A Doyle; Joanna M Brell; Lillian L Siu Journal: J Clin Oncol Date: 2012-07-09 Impact factor: 44.544
Authors: Nicolas Floc'h; Carolyn Waugh Kinkade; Takashi Kobayashi; Alvaro Aytes; Celine Lefebvre; Antonina Mitrofanova; Robert D Cardiff; Andrea Califano; Michael M Shen; Cory Abate-Shen Journal: Cancer Res Date: 2012-07-19 Impact factor: 12.701
Authors: Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni Journal: Nat Rev Clin Oncol Date: 2011-11-29 Impact factor: 66.675